STING1 and cancer: Here, we provide evidence that suggests that AhR activity suppresses STING-mediated IFN-I in TNBC, especially in the context of PARPi treatment of BRCA1-deficient cells, and that its inhibition represents a therapeutically viable method to enhance cancer cell-intrinsic STING activity, both alone and in combination with PARPi (Fig. 5).